LAUSR

Radical nephrectomy (RN) or partial nephrectomy (PN) is the standard treatment option for nonmetastatic renal cell carcinoma (RCC). 1 After surgery, adjuvant therapy may be consid-ered, given that unfavorable pathological outcomes are generally related to tumor recurrence. In a recent randomized trial (KEYNOTE-564), adjuvant pembrolizumab was more bene fi cial for disease-free survival than placebo in patients with clear-cell RCC who had a higher risk for recurrence; thus, this treatment may become a standard treatment option in the future. 2 However, the proportion of patients with this criterion in clinical practice remains unknown. Hence, we evaluated the proportion of patients with nonmetastatic RCC eligible for adjuvant pembrolizumab in clinical practice.